

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Research Report 2023

<https://marketpublishers.com/r/G43CF7626D6AEN.html>

Date: December 2023

Pages: 85

Price: US\$ 2,900.00 (Single User License)

ID: G43CF7626D6AEN

Abstracts

Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.

According to QYResearch's new survey, global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market is projected to reach US\$ 38900 million in 2029, increasing from US\$ 14620 million in 2022, with the CAGR of 15.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive

to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Siemens Healthcare

Celerion

ZyVersa Therapeutics, Inc.

Cisbio

Regeneron Pharmaceuticals, Inc.

BioPredictive

Echosens

Genfit

Enterome

NGM Biopharmaceuticals

Segment by Type

Therapeutics

Diagnostics

Segment by Application

Hospital

Clinic

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Therapeutics

1.2.3 Diagnostics

1.3 Market by Application

1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Perspective (2018-2029)

2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Growth Trends
by Region

2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic
Market Size by Region (2018-2023)

2.2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted
Market Size by Region (2024-2029)

2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Dynamics

2.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry
Trends

2.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Drivers

2.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Challenges

2.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue

3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue (2018-2023)

3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Players (2018-2023)

3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue

3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio

3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2022

3.5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Area Served

3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service

3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS BREAKDOWN DATA BY TYPE

4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Type (2018-2023)

4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2024-2029)

5 NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS BREAKDOWN DATA BY APPLICATION

5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Application (2018-2023)

5.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2018-2029)

6.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023)

6.4 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2018-2029)

7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023)

7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size (2018-2029)

8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size by Region (2018-2023)

8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size (2018-2029)

9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size by Country (2018-2023)

9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2018-2029)

10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023)

10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Siemens Healthcare

11.1.1 Siemens Healthcare Company Detail

11.1.2 Siemens Healthcare Business Overview

11.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.1.4 Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.1.5 Siemens Healthcare Recent Development

11.2 Celerion

11.2.1 Celerion Company Detail

11.2.2 Celerion Business Overview

11.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.2.4 Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.2.5 Celerion Recent Development

11.3 ZyVersa Therapeutics, Inc.

11.3.1 ZyVersa Therapeutics, Inc. Company Detail

11.3.2 ZyVersa Therapeutics, Inc. Business Overview

11.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.3.4 ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.3.5 ZyVersa Therapeutics, Inc. Recent Development

11.4 Cisbio

11.4.1 Cisbio Company Detail

11.4.2 Cisbio Business Overview

11.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.4.4 Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.4.5 Cisbio Recent Development

11.5 Regeneron Pharmaceuticals, Inc.

11.5.1 Regeneron Pharmaceuticals, Inc. Company Detail

11.5.2 Regeneron Pharmaceuticals, Inc. Business Overview

11.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.5.4 Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.5.5 Regeneron Pharmaceuticals, Inc. Recent Development

11.6 BioPredictive

11.6.1 BioPredictive Company Detail

11.6.2 BioPredictive Business Overview

11.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.6.4 BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.6.5 BioPredictive Recent Development

11.7 Echosens

11.7.1 Echosens Company Detail

11.7.2 Echosens Business Overview

11.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.7.4 Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.7.5 Echosens Recent Development

11.8 Genfit

11.8.1 Genfit Company Detail

11.8.2 Genfit Business Overview

11.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.8.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.8.5 Genfit Recent Development

11.9 Enterome

11.9.1 Enterome Company Detail

11.9.2 Enterome Business Overview

11.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction

11.9.4 Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)

11.9.5 Enterome Recent Development

11.10 NGM Biopharmaceuticals

11.10.1 NGM Biopharmaceuticals Company Detail

- 11.10.2 NGM Biopharmaceuticals Business Overview
- 11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
- 11.10.4 NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- 11.10.5 NGM Biopharmaceuticals Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Therapeutics

Table 3. Key Players of Diagnostics

Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2018-2023)

Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2024-2029)

Table 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends

Table 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers

Table 12. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges

Table 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players (2018-2023)

Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2022)

Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis

(NASH) Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service

Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2018-2023)

Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2024-2029)

Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2018-2023)

Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2024-2029)

Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2018-2023) & (US\$ Million)

- Table 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2024-2029) & (US\$ Million)
- Table 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 41. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023) & (US\$ Million)
- Table 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029) & (US\$ Million)
- Table 43. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 44. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2018-2023) & (US\$ Million)
- Table 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2024-2029) & (US\$ Million)
- Table 46. Siemens Healthcare Company Detail
- Table 47. Siemens Healthcare Business Overview
- Table 48. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
- Table 49. Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)
- Table 50. Siemens Healthcare Recent Development
- Table 51. Celerion Company Detail
- Table 52. Celerion Business Overview
- Table 53. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
- Table 54. Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)
- Table 55. Celerion Recent Development
- Table 56. ZyVersa Therapeutics, Inc. Company Detail
- Table 57. ZyVersa Therapeutics, Inc. Business Overview
- Table 58. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
- Table 59. ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)
- Table 60. ZyVersa Therapeutics, Inc. Recent Development
- Table 61. Cisbio Company Detail
- Table 62. Cisbio Business Overview
- Table 63. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 64. Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 65. Cisbio Recent Development

Table 66. Regeneron Pharmaceuticals, Inc. Company Detail

Table 67. Regeneron Pharmaceuticals, Inc. Business Overview

Table 68. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 69. Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 70. Regeneron Pharmaceuticals, Inc. Recent Development

Table 71. BioPredictive Company Detail

Table 72. BioPredictive Business Overview

Table 73. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 74. BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 75. BioPredictive Recent Development

Table 76. Echosens Company Detail

Table 77. Echosens Business Overview

Table 78. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 79. Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 80. Echosens Recent Development

Table 81. Genfit Company Detail

Table 82. Genfit Business Overview

Table 83. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 84. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 85. Genfit Recent Development

Table 86. Enterome Company Detail

Table 87. Enterome Business Overview

Table 88. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 89. Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 90. Enterome Recent Development

Table 91. NGM Biopharmaceuticals Company Detail

Table 92. NGM Biopharmaceuticals Business Overview

Table 93. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product

Table 94. NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023) & (US\$ Million)

Table 95. NGM Biopharmaceuticals Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type: 2022 VS 2029

Figure 3. Therapeutics Features

Figure 4. Diagnostics Features

Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2022 VS 2029

Figure 7. Hospital Case Studies

Figure 8. Clinic Case Studies

Figure 9. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered

Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region: 2022 VS 2029

Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players in 2022

Figure 14. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2022)

Figure 15. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2022

Figure 16. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2018-2029)

Figure 18. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2018-2029)

Figure 22. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2018-2029)

Figure 30. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2018-2029)

Figure 38. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)

- Figure 39. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 40. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2018-2029)
- Figure 42. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 43. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 44. Siemens Healthcare Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 45. Celerion Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 46. ZyVersa Therapeutics, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 47. Cisbio Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 48. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 49. BioPredictive Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 50. Echosens Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 51. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 52. Enterome Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 53. NGM Biopharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2018-2023)
- Figure 54. Bottom-up and Top-down Approaches for This Report
- Figure 55. Data Triangulation
- Figure 56. Key Executives Interviewed

I would like to order

Product name: Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Research Report 2023

Product link: <https://marketpublishers.com/r/G43CF7626D6AEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G43CF7626D6AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

